The future of macrolide antibiotics: Modification and new discoveries

Initially isolated in 1950 from a Streptomyces strain, macrolides have evolved to address chronic lung inflammatory diseases and respiratory tract infections. However, with the emergence of bacterial resistance, there is an urgent need for new antibiotics to alleviate the current situation. The structure of macrolides is characterized by a macrocyclic lactone ring with 14, 15, or 16 atoms, often linked to sugars via glycosidic bonds. The mode of action involves inhibiting bacterial protein synthesis by binding to the ribosome, though recent studies suggest selective interference with certain proteins. Resistance mechanisms include diminished drug binding and macrolide efflux, facilitated by efflux pumps of the mef and msr families. The future of macrolides lies in modifying existing drugs, such as erythromycin, and discovering new antibiotics through genome mining and serendipitous findings. Advanced synthetic platforms can offer promising avenues for creating novel macrolide structures. These strategies offer hope for overcoming bacterial resistance. The article concludes with an optimistic outlook on the future of macrolide antibiotics, driven by continuous scientific innovation and exploration of natural and synthetic pathways.